Bioter S.A. Logo

Bioter S.A.

BIOT.AT

(0.0)
Stock Price

0,30 EUR

-8.72% ROA

10.11% ROE

-0.39x PER

Market Cap.

4.518.396,00 EUR

-153.76% DER

0% Yield

-2340.88% NPM

Bioter S.A. Stock Analysis

Bioter S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bioter S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Bioter S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bioter S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Bioter S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bioter S.A. Revenue
Year Revenue Growth
2012 6.364.000
2013 4.784.000 -33.03%
2014 4.946.000 3.28%
2015 1.227.000 -303.1%
2016 551.000 -122.69%
2017 180.000 -206.11%
2018 177.000 -1.69%
2019 250.000 29.2%
2020 228.000 -9.65%
2021 246.000 7.32%
2022 252.000 2.38%
2023 378.000 33.33%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bioter S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bioter S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 6.082.000
2013 2.863.000 -112.43%
2014 2.169.000 -32%
2015 1.093.000 -98.44%
2016 726.000 -50.55%
2017 721.000 -0.69%
2018 966.000 25.36%
2019 623.000 -55.06%
2020 695.000 10.36%
2021 505.000 -37.62%
2022 1.419.000 64.41%
2023 1.192.000 -19.04%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bioter S.A. EBITDA
Year EBITDA Growth
2012 -31.330.000
2013 -6.927.000 -352.29%
2014 -3.496.000 -98.14%
2015 -2.380.000 -46.89%
2016 -5.545.000 57.08%
2017 -6.592.000 15.88%
2018 -5.807.000 -13.52%
2019 -618.000 -839.64%
2020 -2.033.999 69.62%
2021 -1.286.000 -58.16%
2022 -692.000 -85.84%
2023 -1.302.000 46.85%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bioter S.A. Gross Profit
Year Gross Profit Growth
2012 -27.548.000
2013 -7.179.000 -283.73%
2014 -4.026.000 -78.32%
2015 -2.261.000 -78.06%
2016 -5.205.000 56.56%
2017 -6.483.000 19.71%
2018 -4.992.000 -29.87%
2019 -68.000 -7241.18%
2020 -1.454.000 95.32%
2021 -935.000 -55.51%
2022 -15.000 -6133.33%
2023 -156.000 90.38%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bioter S.A. Net Profit
Year Net Profit Growth
2012 -35.805.000
2013 -13.722.000 -160.93%
2014 -13.518.000 -1.51%
2015 -10.173.000 -32.88%
2016 -18.325.000 44.49%
2017 -17.515.000 -4.62%
2018 -12.796.000 -36.88%
2019 -8.891.000 -43.92%
2020 6.057.000 246.79%
2021 -8.809.000 168.76%
2022 -9.677.000 8.97%
2023 -13.534.000 28.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bioter S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -2
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 0 0%
2021 -1 0%
2022 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bioter S.A. Free Cashflow
Year Free Cashflow Growth
2012 -8.598.000
2013 -6.645.000 -29.39%
2014 -9.706.000 31.54%
2015 -8.770.000 -10.67%
2016 -7.173.000 -22.26%
2017 -13.895.000 48.38%
2018 -7.045.000 -97.23%
2019 -6.360.000 -10.77%
2020 -9.098.000 30.09%
2021 -5.896.000 -54.31%
2022 -9.444.000 37.57%
2023 -1.969.000 -379.63%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bioter S.A. Operating Cashflow
Year Operating Cashflow Growth
2012 -8.399.000
2013 -6.527.000 -28.68%
2014 -9.584.000 31.9%
2015 -8.758.000 -9.43%
2016 -7.162.000 -22.28%
2017 -13.878.000 48.39%
2018 -7.045.000 -96.99%
2019 -6.360.000 -10.77%
2020 -9.098.000 30.09%
2021 -5.846.000 -55.63%
2022 -9.444.000 38.1%
2023 -1.969.000 -379.63%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bioter S.A. Capital Expenditure
Year Capital Expenditure Growth
2012 199.000
2013 118.000 -68.64%
2014 122.000 3.28%
2015 12.000 -916.67%
2016 11.000 -9.09%
2017 17.000 35.29%
2018 0 0%
2019 0 0%
2020 0 0%
2021 50.000 100%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bioter S.A. Equity
Year Equity Growth
2012 -568.999
2013 -14.336.000 96.03%
2014 -25.329.999 43.4%
2015 -35.437.000 28.52%
2016 -53.879.000 34.23%
2017 -71.442.000 24.58%
2018 -85.018.000 15.97%
2019 -93.853.000 9.41%
2020 -88.037.000 -6.61%
2021 -96.857.000 9.11%
2022 -106.521.000 9.07%
2023 -118.296.000 9.95%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bioter S.A. Assets
Year Assets Growth
2012 142.566.000
2013 126.832.000 -12.41%
2014 118.958.000 -6.62%
2015 99.728.000 -19.28%
2016 90.898.000 -9.71%
2017 89.845.000 -1.17%
2018 86.753.000 -3.56%
2019 88.149.000 1.58%
2020 86.239.000 -2.21%
2021 84.748.000 -1.76%
2022 85.087.000 0.4%
2023 81.234.000 -4.74%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bioter S.A. Liabilities
Year Liabilities Growth
2012 143.135.000
2013 141.168.000 -1.39%
2014 144.288.000 2.16%
2015 135.165.000 -6.75%
2016 144.777.000 6.64%
2017 161.287.000 10.24%
2018 171.771.000 6.1%
2019 182.002.000 5.62%
2020 174.276.000 -4.43%
2021 181.605.000 4.04%
2022 191.608.000 5.22%
2023 193.523.000 0.99%

Bioter S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-0.7
Price to Earning Ratio
-0.39x
Price To Sales Ratio
9.05x
POCF Ratio
-0.78
PFCF Ratio
-0.78
Price to Book Ratio
-0.04
EV to Sales
365.24
EV Over EBITDA
-75.53
EV to Operating CashFlow
-31.46
EV to FreeCashFlow
-31.46
Earnings Yield
-2.58
FreeCashFlow Yield
-1.28
Market Cap
0,00 Bil.
Enterprise Value
0,18 Bil.
Graham Number
10.51
Graham NetNet
-10.45

Income Statement Metrics

Net Income per Share
-0.7
Income Quality
0.5
ROE
0.1
Return On Assets
-0.14
Return On Capital Employed
0.02
Net Income per EBT
0.97
EBT Per Ebit
4.8
Ebit per Revenue
-5.02
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
3.03
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.1
Operating Profit Margin
-5.02
Pretax Profit Margin
-24.11
Net Profit Margin
-23.41

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.35
Free CashFlow per Share
-0.35
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.04
Return on Tangible Assets
-0.09
Days Sales Outstanding
14698.75
Days Payables Outstanding
545.83
Days of Inventory on Hand
73.4
Receivables Turnover
0.02
Payables Turnover
0.67
Inventory Turnover
4.97
Capex per Share
0

Balance Sheet

Cash per Share
0,21
Book Value per Share
-6,71
Tangible Book Value per Share
-3.56
Shareholders Equity per Share
-7.04
Interest Debt per Share
11.43
Debt to Equity
-1.54
Debt to Assets
2.23
Net Debt to EBITDA
-73.66
Current Ratio
0.12
Tangible Asset Value
-0,06 Bil.
Net Current Asset Value
-0,17 Bil.
Invested Capital
-219056000
Working Capital
-0,17 Bil.
Intangibles to Total Assets
-0.65
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
110000
Debt to Market Cap
40.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bioter S.A. Dividends
Year Dividends Growth
2000 0
2001 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%

Bioter S.A. Profile

About Bioter S.A.

Bioter S.A. operates as a technical construction company in Greece and internationally. It is involved in the execution of various projects, such as roads, ports, industrial-energy, electromechanical-communications, airports, war industries factories, etc., as well as private projects, such as offices, banks, car stations, etc. The company was founded in 1961 and is based in Athens, Greece.

CEO
Mr. Ioannis Konstantinopoulos
Employee
4
Address
Eftychidou 45
Athens, 11634

Bioter S.A. Executives & BODs

Bioter S.A. Executives & BODs
# Name Age
1 Mr. Milingos Georgios
Chief Accountant
70
2 Mr. Ioannis Konstantinopoulos
General Director & Director
70
3 Ms. Antonia Katsarou
Executive Vice Chairman of Board
70

Bioter S.A. Competitors